Abstract Details
|
Gaelle E. Doucet, PhD
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| Christopher Skidmore, MD (Thomas Jefferson University) | Dr. Skidmore has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Skidmore has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for SALTZ MONGELUZZI BENDESKY LLC. The institution of Dr. Skidmore has received research support from Neuropace. The institution of Dr. Skidmore has received research support from Jazz Pharmaceuticals. |
| No disclosure on file | |
| Michael R. Sperling, MD, FAAN (Thomas Jefferson University) | Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for International Medical Press. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Projects for Knowledge. The institution of Dr. Sperling has received research support from SK Life Science. The institution of Dr. Sperling has received research support from UCB Pharma . The institution of Dr. Sperling has received research support from Takeda. The institution of Dr. Sperling has received research support from Neurelis. The institution of Dr. Sperling has received research support from Engage Therapeutics . The institution of Dr. Sperling has received research support from Medtronic. The institution of Dr. Sperling has received research support from Cavion. The institution of Dr. Sperling has received research support from Xenon Pharma. The institution of Dr. Sperling has received research support from Cerevel. The institution of Dr. Sperling has received research support from National Institutes of Health . The institution of Dr. Sperling has received research support from DARPA. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Vice President with Epilepsy Consortium . |
| No disclosure on file | |
| Helen Tremlett, PhD, BPharm (University of British Columbia) | Dr. Tremlett has nothing to disclose. |